MIAMI (CBSMiami) Scientists are working to create a robot that can detect all kinds of emotions. They say the benefits could help patients with a range of mental health disorders.

The robot is called Abel, and it is learning to smile, snarl, and frown. Twenty motors under his artificial skin give the robot emotions just like us. Engineers hope someday Abel will be a friend for people with behavioral, social, or cognitive disorders like autism or Alzheimers.

We want Abel to know how people are feeling to keep them healthy, not just physically, but mentally and emotionally, researcher Lorenzo Cominelli said.

To make Abel look eerily real, engineers teamed up with special effects artist Gustav Hoegen. His company has created animatronics for Hollywood hits Star Wars and Jurassic Park.

Right now, someone has to wear sensors for the robot to recognize their emotions. The next step may seem like something out of science fiction. Researchers say they want to give Abel a human brain with the help of tissue taken from stem cells.

Organoids are basically an aggregate of stem cells which self-assemble and self-organize to resemble the structure and function of a mini-human organ, researcher Arti Ahluwalia said.

Scientists say that would allow Abel to read our expressions all on his own. And if theyre successful, expect the team and Abel to look a bit smug.

Researchers acknowledge they are years away from their goal, but they believe Abel will one day not only be able to recognize emotions on his own but be able feel them too.

View post:
Scientists Working On Robot That Can Detect All Kinds Of Emotions In Hopes Of Helping Patients With Mental Health Disorders - CBS Miami

Skin Stem Cells Comments Off on Scientists Working On Robot That Can Detect All Kinds Of Emotions In Hopes Of Helping Patients With Mental Health Disorders – CBS Miami | June 8th, 2021

In March, Australian scientists announced a worldwide important model of an early human Embryo, blastoids, using skin cells. The finding was crucial because it enables researchers to explore the reasons for infertility, developmental abnormalities, and miscarriage in a period of human development that is not yet accessible without human embryos. The International Stem Cell Science Organization published.

In the past week of May, new criteria for early human life research are to be conducted. The International Stem Cell Research Society guidelines include current progress such as the iBlastoid models and offer several recommendations that assist scientists in understanding more about the early phases of human life. The procedures also include: There are also apparent indications, such as genetic tampering, of what should not be permitted.

The most significant proposal is to modify the 14-day limit, a regulatory line-in-the-sand that scientists cannot experiment with human embryos in Australia and nearly a dozen nations. The 14-day limit stems from the 1980s when human seeds could not be grown longer than roughly six days after fertilization. Although modern technology currently allows scientists to cultivate embryos beyond 14 days in the laboratory, the rule is that research to take them further has not taken place.

Why fourteen days? On day 14, a human embryo is no longer a cell ball. It develops the primitive stripe, the beginning of the neural cord, eventually leading to the central nervous system. At a period when embryo research was a reasonably novel notion with the twin advantage of creating confidence while at the same time allowing space for early human development study, the deadline offered total certainty. Since scientists can cultivate human embryos for longer, revisions to these standards have been called for a long time.

What restrictions can instead be established to manage research on human embryos? The recommendations suggest that researchers who wish to develop human briefings above the two-week mark should assess their project by case to determine when they have to terminate investigations, subject to many rounds of assessment. The recommendation of the ISSCR for embryos or models from human stem cells, like the blastoids produced by Professor Jose Polo with his colleagues at Monash University, is of particular relevance to Australian science.

The new rules declare because most laws worldwide do not regard such embryo models to be identical to human embryos that they are not subject to the 14-day rule limitations. This statement directly contradicts the guidelines with the Australian law of 2002, which defines an embryo not only as an egg and sperm product. But as an embryo created by any other process that initiates organized development of a biological entity with a human nuclear genome or an altering human nuclear genome that may develop.

iBlastoids can simulate several elements of embryo development, making it a fantastic study tool. However, they have sufficient molecular and cellular composition modifications that scientists see as differing from human embryos. However, under Australian laws, iBlastoids are subject to existing human embryo research regulations, including a research license and the fourteen-day limit, as the National Health and Medical Research Council decided. Australian iBlastoid research will require discussion on the concept of a human embryo and maybe regulatory reform under the latest international principles.

To identify reasons for ingratitude, developmental anomalies, and malfunction, we have operated with human embryos and human embryo models ethically and responsibly. A timely reminder is made of the complete and bold ISSCR standards, which frequently need a change in the legislation to comply with science and allow advances such as IVF to occur.

Read the original post:
Embryo research law requires updating to match up with science - Cleveland American

Skin Stem Cells Comments Off on Embryo research law requires updating to match up with science – Cleveland American | June 8th, 2021

Every skin care fanatic has a favorite step of their routinethe layer of the ritual that brings them the most joy. And while I love the tender act of massaging in a dense face cream or slipping on an oil at night, there is nothing I appreciate more than washing my face. Yes, it's a semi-controversial skin care take (as controversial as those can be), but it's true: I love the ritual of cleaning my skin.

But face washes are a deceptively tricky category. For some time, the reigning options were of the strip-your-face variety. (You know the ones: Those sudsy numbers that left you feeling squeaky and dry.) But now, there are so many that experiment with textures, infuse deliciously hydrating actives, and elevate sensorial experiencesand finally, they're getting due attention.

There's no better example of this than the cleansing balm. (Even saying "cleansing balm" feels like slipping into a cashmere sweater.) The subcategory of face washes is marked by their thick, gel-cream texture and hydrating benefits; of course, there are subtle differences between them that make them unique, but that's the throughline.

Now, if all of the above has you thinking you need to get your hands on one, here are our favorites for you to try. Enjoy, won't you?

Read more here:
The Creamiest, Dreamiest Way To Wash Your Face: 13 Must-Try Cleansing Balms - mindbodygreen.com

Skin Stem Cells Comments Off on The Creamiest, Dreamiest Way To Wash Your Face: 13 Must-Try Cleansing Balms – mindbodygreen.com | June 8th, 2021

Abel has 20 motors under his human-like skin that allow him to show feelings just like us.

LONDON, UK Scientists in Italy are working to create a robot that can detect all kinds of emotions.

The robot is called Abel, and it is learning to smile, snarl, and frown. Twenty motors under his artificial skin give the robot "emotions" just like us. Engineers hope someday Abel will be a friend for people with behavioral, social, or cognitive disorders like autism or Alzheimer's.

Researcher Lorenzo Cominelli says, "We want Abel to know how people are feeling - to keep them healthy, not just physically, but mentally and emotionally."

To make Abel look eerily real, engineers teamed up with special effects artist Gustav Hoegen. His company has created animatronics for Hollywood hits "Star Wars" and "Jurassic Park."

Right now, someone has to wear sensors for the robot to recognize their emotions. The next step may seem like something out of science fiction. Researchers say they want to give Abel a human brain with the help of tissue taken from stem cells.

Researcher Arti Ahluwalia says, "Organoids are basically an aggregate of stem cells which self-assemble and self-organize to resemble the structure and function of a mini-human organ." Scientists say that would allow Abel to read our expressions all on his own. And if they're successful, expect the team and Abel to look a bit smug.

Researchers acknowledge they are years away from their goal, but they believe Abel will one day not only be able to recognize emotions on his own but be able feel them too.

Go here to read the rest:
Humanoid robot has super realistic facial expressions and it's kind of eerie - KHOU.com

Skin Stem Cells Comments Off on Humanoid robot has super realistic facial expressions and it’s kind of eerie – KHOU.com | June 8th, 2021

HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (Nasdaq: KRBP)

Expansion of in-house cGMP manufacturing facility to provide support to the Company's clinical trials. Therapeutic doses expected to be ready for first in-human dosing in 3Q-2021.

Mr. Ignacio Nez, a 20-year industry veteran in global operations and manufacturing, is joining the Kiromic team to take the company to the next level and to scale up cGMP manufacturing capabilities internally.

Kiromic is an immuno-oncology company using Artificial Intelligence (AI) to identify critical markers in solid tumors to develop Allogeneic CAR-T cell therapy.

Kiromics CAR-T technology addresses critical efficacy and safety issues by developing switches to control T-cell activity reducing cell exhaustion and cytokine release syndrome among others.

-------------

Expansion of in-house cGMP manufacturing facility

In support of the upcoming INDs, Kiromic is expanding its HQ in Houston, TX. To their current cGMP, R&D labs, vivarium and offices, Kiromic is adding an adjacent space where more cGMP clean rooms, QC, QA and regulatory, offices and ultra-cold storage will have place.

This new expansion will add up to a total of approximately 30,000 square feet and will enable supporting Kiromic significant growth as the company approaches the clinical phase.

Appointment of Chief Operating and Manufacturing Officer

Mr. Ignacio Nez MSCHE, MBB has been appointed as Chief Operating Officer and Manufacturing Officer.

Mr. Nez will play a key role in expanding the scale up of Kiromics operations, including manufacturing, taking the company from pre-IND status to the clinical phase and eventually to commercial phase.

Mr. Nez has over 20 years of global experience in corporate functions including manufacturing, research, operational excellence and strategy. He has held senior leadership positions in companies including General Electric, Johnson & Johnson and Novartis. Most recently, he was the Executive Director of Manufacturing at the Gene Therapy Program of the University of Pennsylvania.

Before that, he was the Head of Manufacturing Strategy and Operations Excellence at Novartis, where he was charged with transforming manufacturing operations in support of the ramp up of Kymriah, the first FDA-approved CAR-T cell therapy, which was developed at the University of Pennsylvania.

Mr. Nez holds an MSC in Chemical Engineering from the University of Granada.

CEO of Kiromic, Maurizio Chiriva-Internati, DBSc, PhDs

Kiromic believes it has the key to resolve the current challenges in cell therapy and I believe we will become the reference and lead the industry going forward.

Cell Therapy Manufacturing: Autologous (patient) vs. Allogeneic (healthy donor)

The table below outlines the current cell therapy manufacturing challenges which Kiromic allogeneic cell manufacturing expects to resolve and which Mr. Nez will advance.

CAR-T technology challenges

AutologousCAR-T

KiromicAllogeneic

CAR-T

Safety

CRS

(cytokine release syndrome)

-

+

CRES

(T-cell related encephalopathy syndrome)

-

+

Efficacy

Efficacy

++

++++ (*)

Indication

BloodCancers

SolidTumors

T-cell overstimulation

-

+

T-cell exhaustion

-

+

Tumor immune suppressive microenvironment

-

+

Tumor specific antigens (shedding)

CD19

multipletargets

Manufacturing

Patients variation & manufacturing success

-

+

Lead time(autologous vs. off-the-shelf)

17-30 days

None

Cost of Manufacturing (per patient)

++++

+

Application

Order of treatment application

3rd Line

TBD

Treatment Setting

24 Daysin-patient

24 hoursin-patient (**)

(*) based upon Kiromic's pre-clinical projections, AACR posters (**) as filed in IND to the FDA (May 2021).

COMO of Kiromic, Mr. Ignacio Nez stated:

"I am impressed by Kiromics end-to-end approach to cell therapy as I believe they address almost every known issue in current cell therapies.

Expanded Kiromic in-house manufacturing capabilities are capital efficient and are optimized to deliver the capacity projections, making manufacturing a competitive advantage and not a challenge for the company.

I believe that this technology is meant to change the cell and gene therapy landscape, reshaping the future approach to cancer treatment.

I am humbled to join the team at this critical juncture."

CMO of Kiromic, Scott Dahlbeck, MD, PharmD stated:

Kiromic is pleased to obtain the clinical manufacturing expertise of Mr. Nez, whose expertise and biopharmaceutical background I believe will serve to capitalize on the cellular therapy production capabilities of Kiromic, leading to a new era in immuno-oncology treatments for solid tumors."

CSIO of Kiromic, Mr. Gianluca Rotino stated:

"I believe all of our cell therapy manufacturing is novel and resolves key industry challenges.

It is my opinion, that our manufacturing technology will be very much sought after by pharma companies and cell therapy industry players.

Our cell therapy IPs portfolio is very strong.

This manufacturing expansion and bringing Mr. Nunez to Kiromic are strategically important milestones that makes us ready to face the challenges of the clinical trials and puts us on the path of commercial viability of our novel therapy."

CFO of Kiromic, Mr. Tony Tontat stated:

"Capital efficiency is what we strove to deliver with our investments as we were building out our cGMP facility.

We are happy to receive this additional validation of capital efficiency from an industry veteran like Mr. Nez."

How Our KB-PD1 Live Cell Therapy CAR-T Improves CAR-T Market:

Marketed andtraditional CAR-T

Kiromic KB-PD1

Malignancies(Cancer Type)

Hematologic

Solid Tumors

Live Cell Origin

Autologous

Live Cells from

pre-treatment patients

Allogeneic

Live Cells from

Follow this link:
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Nez as Chief...

IPS Cell Therapy Comments Off on Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Nez as Chief… | June 8th, 2021

AMSBIO reports upon a publication** that cites how its STEM-CELLBANKER animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinsons Disease that will soon be going into clinical trials.

Parkinsons disease is one of the most common neurodegenerative diseases worldwide. Its main features include motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability, though non-motor symptoms are often also present. Currently the main therapy for Parkinsons disease consists of augmentation of dopamine levels in the brain via dopamine supplements or agonists or by inhibiting dopamine degradation. Treatment using this methodology is symptomatic but not long-lasting, and unfortunately has no neuroprotective effect. Cell therapy with grafts of human fetal tissue from the ventral mesencephalon have been carried out successfully, with multiple reports of long-term benefits.

A pioneering study from the Centre for Stem Cell Biology at the Memorial Sloan Kettering Cancer Centre (USA) has focused on developing stem cell-derived midbrain dopamine progenitors for the treatment of Parkinsons Disease. This study highlighted, amongst other things, that scientists have been able to demonstrate the efficacy of STEM-CELLBANKER to store, thaw and then recover these manufactured cells for clinical use in patients.

STEM-CELLBANKER is a ready-to-use, chemically defined, animal-free freezing medium manufactured under GMP conditions. It is optimized for embryonic stem (ES) and induced pluripotent stem (iPS) cell storage, as well as being a suitable solution for the cryopreservation of other fragile cell types. Containing only European or US Pharmacopoeia graded ingredients, STEM-CELLBANKER is the optimal choice for storage of cells developed for cell therapy applications. It is also available as a DMSO free formulation. STEM-CELLBANKER significantly increases cell viability while maintaining cell pluripotency, normal karyotype and proliferation ability after freeze-thaw. STEM-CELLBANKER is ready-to-use and requires no special devices, such as a controlled rate freezer, in order to achieve consistently high viabilities following resuscitation from cryopreservation, even over extended long-term storage.

To read the Parkinsons Disease cell therapy paper in full please visithttps://bit.ly/3eYwZ5L. For further information including a video introduction to STEM-CELLBANKER please visithttps://www.amsbio.com/stem-cell-cryopreservation/or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 /info@amsbio.com.

Excerpt from:
Cryopreservation Media helps in Development of a Cell Therapy for Parkinson's Disease - Microbioz India

IPS Cell Therapy Comments Off on Cryopreservation Media helps in Development of a Cell Therapy for Parkinson’s Disease – Microbioz India | June 8th, 2021

Financing Provides Support to the Company’s Strategic Objectives Across All Its Plant Franchises. Financing Provides Support to the Company’s Strategic Objectives Across All Its Plant Franchises.

See original here:
22nd Century Announces $40 Million Common Stock Registered Direct Offering

Global News Feed Comments Off on 22nd Century Announces $40 Million Common Stock Registered Direct Offering | June 8th, 2021

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

See the original post:
BetterLife Closes $2.61 Million Marketed Public Offering

Global News Feed Comments Off on BetterLife Closes $2.61 Million Marketed Public Offering | June 8th, 2021

BUFFALO, N.Y., June 07, 2021 (GLOBE NEWSWIRE) --  22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced new initiatives to strengthen and maximize revenue opportunities in its hemp/cannabis franchise. Included in these developments is the announcement of strategic partnerships with two plant breeders in the northern and southern hemispheres providing the Company with year-round growing capabilities, close partnership activities being conducted with Aurora Cannabis, and the establishment of a newly created Canadian subsidiary. These newest developments further support 22nd Century’s plans for multiple avenues of hemp/cannabis revenue that will begin to be realized in late 2021.

View original post here:
22nd Century Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis Franchise

Global News Feed Comments Off on 22nd Century Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis Franchise | June 8th, 2021

VALNEVA

View original post here:
Déclaration d’actions et de droits de vote de la société Valneva SE – Mai 2021

Global News Feed Comments Off on Déclaration d’actions et de droits de vote de la société Valneva SE – Mai 2021 | June 8th, 2021

Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021.

Read this article:
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021

Global News Feed Comments Off on Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021 | June 8th, 2021

Attachment

See the rest here:
Sanofi launches its new global employee share ownership plan

Global News Feed Comments Off on Sanofi launches its new global employee share ownership plan | June 8th, 2021

The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease

Read the original:
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

Global News Feed Comments Off on FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease | June 8th, 2021

Programs now available to support patients and families with their treatment journey

Read the original here:
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

Global News Feed Comments Off on Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™ | June 8th, 2021

PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021.

Read more:
Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference

Global News Feed Comments Off on Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference | June 8th, 2021

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appointments of industry veterans, Heather Behanna, Ph.D., principal of SR One, and Deepa Prasad, managing director of WestRiver Group, to its board of directors effective June 15, 2021.

See more here:
Design Therapeutics Expands Board of Directors with Key Appointments

Global News Feed Comments Off on Design Therapeutics Expands Board of Directors with Key Appointments | June 8th, 2021

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:20 p.m. ET.

Read the rest here:
Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Global News Feed Comments Off on Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference | June 8th, 2021

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at 5:30 p.m. Eastern Time.

See the original post here:
Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Global News Feed Comments Off on Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference | June 8th, 2021

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven’s Downtown Crossing revitalization project. Arvinas will lease three of the 10 floors at 101 College and this space will serve as the Company’s headquarters beginning in 2024.

See more here:
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

Global News Feed Comments Off on Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven | June 8th, 2021

EMERYVILLE, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen today announced the company will be participating in the upcoming Goldman Sachs Annual Global Healthcare Virtual Conference.

Read more:
Zymergen to Present at Goldman Sachs Annual Global Healthcare Conference

Global News Feed Comments Off on Zymergen to Present at Goldman Sachs Annual Global Healthcare Conference | June 8th, 2021